Comparative Pharmacology
Head-to-head clinical analysis: REQUIP XL versus ROPINIROLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REQUIP XL versus ROPINIROLE HYDROCHLORIDE.
REQUIP XL vs ROPINIROLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ropinirole is a non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown.
Ropinirole is a non-ergoline dopamine agonist with high affinity for D2 and D3 dopamine receptors, particularly D3. It stimulates postsynaptic dopamine receptors in the striatum, compensating for dopamine deficiency in Parkinson's disease and modulating dopaminergic pathways in restless legs syndrome.
Initial: 2 mg orally once daily for weeks 1-2, then titrate as needed; maintenance: 8-24 mg orally once daily.
Initial: 0.25 mg orally three times daily; titrate weekly by increments of 0.25 mg three times daily up to 1 mg three times daily, then 0.5 mg three times daily up to 3 mg three times daily; maximum 8 mg three times daily (24 mg/day).
None Documented
None Documented
Approximately 6 hours (range 4-8 hours) for ropinirole; terminal half-life in elderly or hepatic impairment may be prolonged up to 10-12 hours. Clinically, steady-state achieved within 2 days of dosing.
Terminal elimination half-life: 5-6 hours in young healthy adults; 6-8 hours in elderly. Clinically, steady-state achieved within 2 days.
Renal: 60% (mainly metabolites, <10% unchanged); fecal/biliary: 20%; total excretion accounts for >80% of dose.
Renal: 88% (primarily as metabolites, <10% unchanged). Fecal: <5%.
Category C
Category A/B
Dopamine Agonist
Dopamine Agonist